US FDA rejects Amgen's Xgeva in prostate cancer; more data needed
This article was originally published in Scrip
Executive Summary
Amgen's late evening revelation that the US FDA rejected the company's supplemental biologics license application (sBLA) for its RANK ligand inhibitor Xgeva (denosumab 120mg) as a treatment for men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases came as little surprise, given regulators already had expressed concern about the lack of a survival benefit in that indication with the drug and the significant adverse events, such as osteonecrosis of the jaw (ONJ).
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.